Clinical Trial Update: Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders [Phase 2]

View source ↗

Summary

Phase 2 trial investigating fecal microbiota transplant followed by re-introduction of anti-PD-1 therapy (pembrolizumab or nivolumab) for anti-PD-1 non-responde…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Small Intestine Adenocarcinoma

Drugs mentioned

• Fecal microbiota transplant (fecal microbiota transplant)
• Pembrolizumab (pembrolizumab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING